Multiple Site Place-of-Care Manufactured Anti-CD19 CAR-T Cells Induce High Remission Rates in B Cell Malignancy Patients

The authors developed an anti-CD19 CAR comprised of the 4-1BB co-stimulatory and TNFRSF19 transmembrane domains, showing anti-tumor efficacy in an in vivo xenograft lymphoma model.